Amyndas features in BioWorld, the biopharmaceuticals news source from Thomson Reuters: Amyndas recent developments caught the interest of the international press, with BioWorld publishing an article about Amyndas on July 17. In this article, Amyndas is presented as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders, that could be more potent than other complement inhibitors. The article titled “Two- pronged Amyndas targets complement-based anti-inflammatories” can be accessed at: http://www.bioworld.com/content/two-pronged-amyndas-targets-complement-based-anti-inflammatories

University of Pennsylvania researchers have been searching for ways to prevent, halt and reverse periodontitis. In a report published in the Journal of Immunology, they describe a promising new target: a component of the immune system called complement. Treating monkeys with a complement inhibitor successfully prevented the inflammation and bone loss that is associated with periodontitis, making this a promising drug for treating humans with the disease.

A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States.

John Lambris, the Dr. Ralph and Sallie Weaver Professor of Research Medicine in the department of pathology and laboratory medicine at Penn’s Perelman School of Medicine, is part of an $8 million European Union FP7 grant, which has been awarded to a consortium of academic institutions and the biotech company called Amyndas Pharmaceuticals (based on Penn technology developed in the Lambris lab).

Almanac, Vol. 60, No. 19

On February 10, 2014 in the article entitled “Amyndas: Complement shutdown” Amyndas Pharmaceuticals is presented in BioCentury as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders that could be more potent than other complement inhibitors.